Study finds dual receptor beta-agonist promotes healthy weight loss
Drug Discovery World
MAY 30, 2024
Atrogi’s CEO, Alexandra Ekman Ryding, said: “This publication highlights strong pre-clinical data relating to ATR-127 and validates our approach for the development of a novel modality for the treatment of obesity. We believe our pioneering dual receptor beta-agonist approach has the potential to transform the obesity treatment landscape.
Let's personalize your content